Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
AiSTI SCIENCE Co., Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This means that each pending matter is being handled by a unique examiner in a separate administrative group. The involvement of 2 distinct art units for 2 pending office actions indicates that the company's biotechnology filings are categorized into different technical specialties.
SALMON, KATHERINE D is the busiest examiner, managing 1 pending office action. This volume is matched by the other distinct examiner in the portfolio. Practitioners must coordinate across 2 distinct art units, which requires a strategy that accounts for different examination styles. Because each of the 2 pending office actions is assigned to a unique examiner, there is no concentration of risk or influence in the current portfolio. This distribution requires the company to maintain 2 separate lines of communication to effectively manage its biotechnology and pharmaceutical prosecution workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18281094 | Method for Detecting Coronavirus Infection | JOHANSEN, PETER N. | 21d |
| 18570878 | METHOD FOR ANALYZING MODIFIED NUCLEOSIDE | SALMON, KATHERINE D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18281094 | Method for Detecting Coronavirus Infection | JOHANSEN, PETER N. | 21d |
| 18570878 | METHOD FOR ANALYZING MODIFIED NUCLEOSIDE | SALMON, KATHERINE D | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18570878 | METHOD FOR ANALYZING MODIFIED NUCLEOSIDE | SALMON, KATHERINE D | 1682 | §102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18281094 | Method for Detecting Coronavirus Infection | JOHANSEN, PETER N. | 1644 | §101 | Final Rejection | 21d | Pending | Sep 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAiSTI SCIENCE Co., Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Katherine D Salmon has the most, with 1 of AiSTI SCIENCE Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
